These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 25859945)

  • 1. Targeting protein-protein interactions for drug discovery.
    Fry DC
    Methods Mol Biol; 2015; 1278():93-106. PubMed ID: 25859945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-molecule inhibitors of protein-protein interactions: how to mimic a protein partner.
    Fry DC
    Curr Pharm Des; 2012; 18(30):4679-84. PubMed ID: 22650256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacophore modelling as a virtual screening tool for the discovery of small molecule protein-protein interaction inhibitors.
    Voet A; Zhang KY
    Curr Pharm Des; 2012; 18(30):4586-98. PubMed ID: 22650262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein-protein interactions as targets for small molecule drug discovery.
    Fry DC
    Biopolymers; 2006; 84(6):535-52. PubMed ID: 17009316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemical libraries dedicated to protein-protein interactions].
    Sperandio O; Villoutreix BO; Morelli X; Roche P
    Med Sci (Paris); 2015 Mar; 31(3):312-9. PubMed ID: 25855285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery?
    Thiel P; Kaiser M; Ottmann C
    Angew Chem Int Ed Engl; 2012 Feb; 51(9):2012-8. PubMed ID: 22308055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations.
    Buchwald P
    IUBMB Life; 2010 Oct; 62(10):724-31. PubMed ID: 20979208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular fields in ligand discovery.
    Gane PJ; Chan AW
    Methods Mol Biol; 2013; 1008():479-99. PubMed ID: 23729264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Domain-based small molecule binding site annotation.
    Snyder KA; Feldman HJ; Dumontier M; Salama JJ; Hogue CW
    BMC Bioinformatics; 2006 Mar; 7():152. PubMed ID: 16545112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein binding site analysis for drug discovery using a computational fragment-based method.
    Ludington JL
    Methods Mol Biol; 2015; 1289():145-54. PubMed ID: 25709039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The topology of drug-target interaction networks: implicit dependence on drug properties and target families.
    Mestres J; Gregori-Puigjané E; Valverde S; Solé RV
    Mol Biosyst; 2009 Sep; 5(9):1051-7. PubMed ID: 19668871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Databases of protein-protein interactions and their use in drug discovery.
    Fuentes G; Oyarzabal J; Rojas AM
    Curr Opin Drug Discov Devel; 2009 May; 12(3):358-66. PubMed ID: 19396737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based computational approaches for small-molecule modulation of protein-protein interactions.
    Xu D; Wang B; Meroueh SO
    Methods Mol Biol; 2015; 1278():77-92. PubMed ID: 25859944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide aptamers for small molecule drug discovery.
    Bardou C; Borie C; Bickle M; Rudkin BB; Colas P
    Methods Mol Biol; 2009; 535():373-88. PubMed ID: 19377984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulating protein-protein interactions: from structural determinants of binding to druggability prediction to application.
    Metz A; Ciglia E; Gohlke H
    Curr Pharm Des; 2012; 18(30):4630-47. PubMed ID: 22650257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bridging Crystal Engineering and Drug Discovery by Utilizing Intermolecular Interactions and Molecular Shapes in Crystals.
    Spackman PR; Yu LJ; Morton CJ; Parker MW; Bond CS; Spackman MA; Jayatilaka D; Thomas SP
    Angew Chem Int Ed Engl; 2019 Nov; 58(47):16780-16784. PubMed ID: 31385643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding thermodynamics discriminates fragments from druglike compounds: a thermodynamic description of fragment-based drug discovery.
    Williams G; Ferenczy GG; Ulander J; Keserű GM
    Drug Discov Today; 2017 Apr; 22(4):681-689. PubMed ID: 27916639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biophysical methods in drug discovery from small molecule to pharmaceutical.
    Holdgate G; Geschwindner S; Breeze A; Davies G; Colclough N; Temesi D; Ward L
    Methods Mol Biol; 2013; 1008():327-55. PubMed ID: 23729258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural biology and drug discovery for protein-protein interactions.
    Jubb H; Higueruelo AP; Winter A; Blundell TL
    Trends Pharmacol Sci; 2012 May; 33(5):241-8. PubMed ID: 22503442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand specificity, privileged substructures and protein druggability from fragment-based screening.
    Barelier S; Krimm I
    Curr Opin Chem Biol; 2011 Aug; 15(4):469-74. PubMed ID: 21411360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.